Antibody Engineering for the Development of Therapeutic Antibodies

• Published in: Molecules and cells Vol. 20; no. 1; pp. 17 - 29
• Main Authors: Kim, S.J. (Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea), Park, Y.W. (Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea), Hong, H.J. (Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea), E-mail: hjhong@kribb.re.kr
• Format: Journal Article
• Language: English
• Published: United States 31.08.2005
• Subjects: Affinity Maturation; Animals; Antibodies - chemistry; Antibodies - physiology; Antibodies, Monoclonal - chemistry; Antibody Affinity; Antibody Engineering; Antibody Fragments; Effector Functions; Human Monoclonal Antibodies; Humanized Antibodies; Humans; MEDICINAL PROPERTIES; Mice; Models, Molecular; Pharmacokinetics; PROPIEDADES MEDICINALES; PROPRIETE PHARMACOLOGIQUE; Protein Engineering - methods; Recombinant Fusion Proteins - chemistry; Technology, Pharmaceutical; Therapeutic Antibodies
• ISSN: 1016-8478; 0219-1032
• DOI: 10.1016/s1016-8478(23)25245-0

Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical industry. There are currently 19 monoclonal antibodies in the market that have been approved by the FDA and over 150 in clinical developments. Driven by innovation and technological developments, therapeutic antibodies are the second largest biopharmaceutical product category after vaccines. Antibodies have been engineered by a variety of methods to suit a particular therapeutic use. This review describes the structural and functional characteristics of antibody and the antibody engineering for the generation and optimization of therapeutic antibodies.